CRBP
Corbus Pharmaceuticals Holdings, Inc. · Healthcare
Insiders bought $126K of Corbus Pharmaceuticals Holdings, Inc. in the last 12 months
1 insider bought on 2 days.
CRBP over the last year
Largest buyers, last 12 months
CRBP after insider buys
3 months after each buy, from the first price a copier could get.
4 buys since 2016 with 3 months of prices.
Every filing
30 insider filings since 2016, newest first
Nishant C Saxena · Chief Business Officer
Yuval Cohen · Chief Executive Officer
Sean F. Moran · Chief Financial Officer
John Kenneth Jenkins · Director
Nishant C Saxena · Chief Business Officer
Dominic Smethurst · Chief Medical Officer
Sean F. Moran · CFO
Yuval Cohen · CEO
Cormorant Asset Management, LP · 10% owner
Cormorant Asset Management, LP · 10% owner
Sean F. Moran · CFO
Yuval Cohen · CEO
Cormorant Asset Management, LP · 10% owner
Cormorant Asset Management, LP · 10% owner
Sean F. Moran · CFO
Sean F. Moran · CFO
Barbara White · Chief Medical Officer
Robert Paul Discordia · COO
Craig Stuart Millian · Chief Commercial Officer
Barbara White · Chief Medical Officer
David P Hochman · Director
David P Hochman · Director
Paris Panayiotopoulos · Director
David P Hochman · Director
David P Hochman · Director
David P Hochman · Director
Avery W Catlin · Director
Barbara White · Chief Medical Officer
David P Hochman · Director
Sean F. Moran · CFO
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.